These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 24789067)
1. Wise regulates bone deposition through genetic interactions with Lrp5. Ellies DL; Economou A; Viviano B; Rey JP; Paine-Saunders S; Krumlauf R; Saunders S PLoS One; 2014; 9(5):e96257. PubMed ID: 24789067 [TBL] [Abstract][Full Text] [Related]
2. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572 [TBL] [Abstract][Full Text] [Related]
3. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. Choi HY; Dieckmann M; Herz J; Niemeier A PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252 [TBL] [Abstract][Full Text] [Related]
4. Lrp4 and Wise interplay controls the formation and patterning of mammary and other skin appendage placodes by modulating Wnt signaling. Ahn Y; Sims C; Logue JM; Weatherbee SD; Krumlauf R Development; 2013 Feb; 140(3):583-93. PubMed ID: 23293290 [TBL] [Abstract][Full Text] [Related]
5. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration. Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG Bone; 2021 Feb; 143():115708. PubMed ID: 33164872 [TBL] [Abstract][Full Text] [Related]
6. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo. Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845 [TBL] [Abstract][Full Text] [Related]
7. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503 [TBL] [Abstract][Full Text] [Related]
8. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355 [TBL] [Abstract][Full Text] [Related]
9. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211 [TBL] [Abstract][Full Text] [Related]
10. Multiple modes of Lrp4 function in modulation of Wnt/β-catenin signaling during tooth development. Ahn Y; Sims C; Murray MJ; Kuhlmann PK; Fuentes-Antrás J; Weatherbee SD; Krumlauf R Development; 2017 Aug; 144(15):2824-2836. PubMed ID: 28694256 [TBL] [Abstract][Full Text] [Related]
11. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945 [TBL] [Abstract][Full Text] [Related]
12. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5. Simpson CA; Foer D; Lee GS; Bihuniak J; Sun B; Sullivan R; Belsky J; Insogna KL Osteoporos Int; 2014 Oct; 25(10):2383-8. PubMed ID: 24927689 [TBL] [Abstract][Full Text] [Related]
13. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. Kamiya N; Kobayashi T; Mochida Y; Yu PB; Yamauchi M; Kronenberg HM; Mishina Y J Bone Miner Res; 2010 Feb; 25(2):200-10. PubMed ID: 19874086 [TBL] [Abstract][Full Text] [Related]
14. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5. Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331 [TBL] [Abstract][Full Text] [Related]
15. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151 [TBL] [Abstract][Full Text] [Related]
16. Peptide-based mediated disruption of N-cadherin-LRP5/6 interaction promotes Wnt signaling and bone formation. Haÿ E; Buczkowski T; Marty C; Da Nascimento S; Sonnet P; Marie PJ J Bone Miner Res; 2012 Sep; 27(9):1852-63. PubMed ID: 22576936 [TBL] [Abstract][Full Text] [Related]
17. The high-bone-mass phenotype of novel transgenic mice with LRP5 A241T mutation. Wang X; Zhang H; Hu L; He J; Jiang Q; Ren L; Yu K; Fu M; Li Z; He Z; Zhu J; Wang Y; Jiang Z; Yang G Bone; 2024 Oct; 187():117172. PubMed ID: 38909879 [TBL] [Abstract][Full Text] [Related]
18. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037 [TBL] [Abstract][Full Text] [Related]
19. Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast. Frey JL; Li Z; Ellis JM; Zhang Q; Farber CR; Aja S; Wolfgang MJ; Clemens TL; Riddle RC Mol Cell Biol; 2015 Jun; 35(11):1979-91. PubMed ID: 25802278 [TBL] [Abstract][Full Text] [Related]
20. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Tu X; Rhee Y; Condon KW; Bivi N; Allen MR; Dwyer D; Stolina M; Turner CH; Robling AG; Plotkin LI; Bellido T Bone; 2012 Jan; 50(1):209-17. PubMed ID: 22075208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]